Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-v5vhk Total loading time: 0 Render date: 2024-06-24T13:02:32.067Z Has data issue: false hasContentIssue false

5a - Mechanisms of disease-related pain in cancer: insights from the study of bone tumors

from Section 2 - Cancer Symptom Mechanisms and Models: Clinical and Basic Science

Published online by Cambridge University Press:  05 August 2011

By
Juan Miguel Jimenez-Andrade  and
Patrick W. Mantyh
Edited by
Charles S. Cleeland ,
Michael J. Fisch  and
Adrian J. Dunn
Juan Miguel Jimenez-Andrade
Affiliation:
University of Arizona
Patrick W. Mantyh
Affiliation:
University of Arizona
Charles S. Cleeland
Affiliation:
University of Texas, M. D. Anderson Cancer Center
Michael J. Fisch
Affiliation:
University of Texas, M. D. Anderson Cancer Center
Adrian J. Dunn
Affiliation:
University of Hawaii, Manoa
Get access

Summary

More than 10 million people are diagnosed with cancer (other than skin cancer) every year, and this number is expected to increase to 15 million per year by 2020. In 2005, cancer caused 7.6 million deaths worldwide. Cancer is a major health problem in the United States: 25% of US mortalities are related to cancer, making it the second leading cause of death.

Despite the increasing prevalence of cancer, improvements in the detection and treatment of most types of cancers have resulted in significantly increased survival rates. Pain is the first sign of cancer for many patients, most of whom will experience moderate to severe pain during the course of their disease and even into survivorship. Cancer-associated pain can be present at any time during the course of the disease, but the frequency and intensity of cancer pain tends to increase as the disease progresses, such that 62% to 86% of patients with advanced-stage cancer experience significant amounts of cancer-induced pain. If cancer patients and survivors, given their increasing life spans, are to remain functional, integrated, and contributing members of society, novel mechanism-based therapies will need to be developed to reduce cancer-related pain.

Cancer pain may arise from different processes: by direct tumor infiltration or involvement, as a result of diagnostic or therapeutic surgical procedures (eg, biopsies, resection), or as a side effect or toxicity related to therapies used to treat cancer (eg, chemotherapy, radiation therapy).

Type
Chapter
Information
Cancer Symptom Science
Measurement, Mechanisms, and Management
 , pp. 32 - 40
Publisher: Cambridge University Press
Print publication year: 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Stewart, BW, Kleihues, P. International Agency for Research on Cancer. World Cancer Report. Lyon: IARC Press, 2003.Google Scholar
,World Health Organization. Cancer: quick cancer facts. Available from: URL: http://www.who.int/cancer. Accessed Aug 12, 2008.
Jemal, A, Siegel, R, Ward, E, Murray, T, Xu, J, Thun, MJ. Cancer statistics, 2007. CA Cancer J Clin 57(1):43–66, 2007.CrossRefGoogle ScholarPubMed
Edwards, BK, Brown, ML, Wingo, PA, et al. Annual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97(19):1407–1427, 2005.CrossRefGoogle ScholarPubMed
Mercadante, S, Arcuri, E. Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev 24(6):425–432, 1998.CrossRefGoogle ScholarPubMed
Portenoy, RK, Payne, D, Jacobsen, P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 81(1–2):129–134, 1999.CrossRefGoogle ScholarPubMed
Beuken-van Everdingen, MH, Rijke, JM, Kessels, AG, Schouten, HC, Kleef, M, Patijn, J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 18(9):1437–1449, 2007.CrossRefGoogle ScholarPubMed
Aalto, Y, Forsgren, S, Kjörell, U, Bergh, J, Franzén, L, Henriksson, R. Enhanced expression of neuropeptides in human breast cancer cell lines following irradiation. Peptides 19(2):231–239, 1998.CrossRefGoogle ScholarPubMed
Julius, D, Basbaum, AI. Molecular mechanisms of nociception. Nature 413(6852):203–210, 2001.CrossRefGoogle ScholarPubMed
Mantyh, PW. Cancer pain and its impact on diagnosis, survival and quality of life. Nat Rev Neurosci 7(10):797–809, 2006.CrossRefGoogle ScholarPubMed
Mercadante, S. Malignant bone pain: pathophysiology and treatment. Pain 69(1–2):1–18, 1997.CrossRefGoogle ScholarPubMed
Coleman, RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27(3):165–176, 2001.CrossRefGoogle ScholarPubMed
Portenoy, RK, Lesage, P. Management of cancer pain. Lancet 353(9165):1695–1700, 1999.CrossRefGoogle ScholarPubMed
Mukherjee, D, Nissen, SE, Topol, EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286(8):954–959, 2001.CrossRefGoogle ScholarPubMed
Mercadante, S. Problems of long-term spinal opioid treatment in advanced cancer patients. Pain 79(1):1–13, 1999.CrossRefGoogle ScholarPubMed
Jemal, A, Siegel, R, Ward, E, et al. Cancer statistics, 2006. CA Cancer J Clin 56(2):106–130, 2006.CrossRefGoogle ScholarPubMed
Honore, P, Luger, NM, Sabino, MA, et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 6(5):521–528, 2000.Google ScholarPubMed
Sabino, MA, Ghilardi, JR, Jongen, JL, et al. Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2. Cancer Res 62(24):7343–7349, 2002.Google ScholarPubMed
Delaissé, JM, Vaes, G. Mechanism of mineral solubilization and matrix degradation in osteoclastic bone resorption. In: Rifkin, BR, Gay, CV, eds. Biology and Physiology of the Osteoclast. Boca Raton: CRC Press, 1992:289–314.Google Scholar
Clohisy, DR, Perkins, SL, Ramnaraine, ML. Review of cellular mechanisms of tumor osteolysis. Clin Orthop Relat Res 373:104–114, 2000.CrossRefGoogle Scholar
Fulfaro, F, Casuccio, A, Ticozzi, C, Ripamonti, C. The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials. Pain 78(3):157–169, 1998.CrossRefGoogle ScholarPubMed
Major, PP, Lipton, A, Berenson, J, Hortobagyi, G. Oral bisphosphonates: a review of clinical use in patients with bone metastases. Cancer 88(1):6–14, 2000.3.0.CO;2-D>CrossRefGoogle ScholarPubMed
Rogers, MJ, Gordon, S, Benford, HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88(12 Suppl):2961–2978, 2000.3.0.CO;2-L>CrossRefGoogle ScholarPubMed
Rodan, GA, Martin, TJ. Therapeutic approaches to bone diseases. Science 289(5484):1508–1514, 2000.CrossRefGoogle ScholarPubMed
Hiraga, T, Tanaka, S, Yamamoto, M, Nakajima, T, Ozawa, H. Inhibitory effects of bisphosphonate (YM175) on bone resorption induced by a metastatic bone tumor. Bone 18(1):1–7, 1996.CrossRefGoogle Scholar
Sasaki, A, Boyce, BF, Story, B, et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 55(16):3551–3557, 1995.Google ScholarPubMed
Sevcik, MA, Luger, NM, Mach, DB, et al. Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis. Pain 111(1–2):169–180, 2004.CrossRefGoogle ScholarPubMed
Tripathy, D, Body, JJ, Bergström, B. Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials. Clin Ther 26(12):1947–1959, 2004.CrossRefGoogle ScholarPubMed
Simonet, WS, Lacey, DL, Dunstan, CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89(2):309–319, 1997.CrossRefGoogle ScholarPubMed
Yasuda, H, Shima, N, Nakagawa, N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139(3):1329–1337, 1998.CrossRefGoogle ScholarPubMed
Tominaga, M, Caterina, MJ, Malmberg, AB, et al. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 21(3):531–543, 1998.CrossRefGoogle ScholarPubMed
Alvarez de la Rosa, D, Zhang, P, Shao, D, White, F, Canessa, CM. Functional implications of the localization and activity of acid-sensitive channels in rat peripheral nervous system. Proc Natl Acad Sci U S A 99(4):2326–2331, 2002.CrossRefGoogle ScholarPubMed
Griffiths, JR. Are cancer cells acidic?Br J Cancer 64(3):425–427, 1991.CrossRefGoogle ScholarPubMed
Ghilardi, JR, Röhrich, H, Lindsay, TH, et al. Selective blockade of the capsaicin receptor TRPV1 attenuates bone cancer pain. J Neurosci 25(12):3126–3131, 2005.CrossRefGoogle ScholarPubMed
Mundy, GR. Bone Remodeling and its Disorders, 2nd ed. London: Martin Dunitz, 1999.Google Scholar
Rubert, CK, Henshaw, RM, Malawer, MM. Orthopedic management of skeletal metastases. In: Body, JJ, ed. Tumor Bone Diseases and Osteoporosis in Cancer Patients: Pathophysiology, Diagnosis, and Therapy. New York: Marcel Dekker, 2000:305–356.Google Scholar
Kundu, N, Yang, Q, Dorsey, R, Fulton, AM. Increased cyclooxygenase-2 (cox-2) expression and activity in a murine model of metastatic breast cancer. Int J Cancer 93(5):681–686, 2001.CrossRefGoogle Scholar
Molina, MA, Sitja-Arnau, M, Lemoine, MG, Frazier, ML, Sinicrope, FA. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 59(17):4356–4362, 1999.Google ScholarPubMed
Iñiguez, MA, Rodriguez, A, Volpert, OV, Fresno, M, Redondo, JM. Cyclooxygenase-2: a therapeutic target in angiogenesis. Trends Mol Med 9(2):73–78, 2003.CrossRefGoogle ScholarPubMed
Masferrer, JL, Leahy, KM, Koki, AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60(5):1306–1311, 2000.Google ScholarPubMed
Williams, CS, Tsujii, M, Reese, J, Dey, SK, DuBois, RN. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 105(11):1589–1594, 2000.CrossRefGoogle ScholarPubMed
Davar, G. Endothelin-1 and metastatic cancer pain. Pain Med 2(1):24–27, 2001.CrossRefGoogle ScholarPubMed
Nelson, JB, Carducci, MA. The role of endothelin-1 and endothelin receptor antagonists in prostate cancer. BJU Int 85(Suppl 2):45–48, 2000.CrossRefGoogle ScholarPubMed
Nelson, JB, Hedican, SP, George, DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1(9):944–949, 1995.CrossRefGoogle ScholarPubMed
Pomonis, JD, Rogers, SD, Peters, CM, Ghilardi, JR, Mantyh, PW. Expression and localization of endothelin receptors: implications for the involvement of peripheral glia in nociception. J Neurosci 21(3):999–1006, 2001.CrossRefGoogle ScholarPubMed
Davar, G, Hans, G, Fareed, MU, Sinnott, C, Strichartz, G. Behavioral signs of acute pain produced by application of endothelin-1 to rat sciatic nerve. Neuroreport 9(10):2279–2283, 1998.CrossRefGoogle ScholarPubMed
Peters, CM, Lindsay, TH, Pomonis, JD, et al. Endothelin and the tumorigenic component of bone cancer pain. Neuroscience 126(4):1043–1052, 2004.CrossRefGoogle ScholarPubMed
Couture, R, Harrisson, M, Vianna, RM, Cloutier, F. Kinin receptors in pain and inflammation. Eur J Pharmacol 429(1–3):161–176, 2001.CrossRefGoogle ScholarPubMed
Fox, A, Wotherspoon, G, McNair, K, et al. Regulation and function of spinal and peripheral neuronal B1 bradykinin receptors in inflammatory mechanical hyperalgesia. Pain 104(3):683–691, 2003.CrossRefGoogle ScholarPubMed
Sevcik, MA, Ghilardi, JR, Halvorson, KG, Lindsay, TH, Kubota, K, Mantyh, PW. Analgesic efficacy of bradykinin B1 antagonists in a murine bone cancer pain model. J Pain 6(11):771–775, 2005.CrossRefGoogle Scholar
Pezet, S, McMahon, SB. Neurotrophins: mediators and modulators of pain. Annu Rev Neurosci 29:507–538, 2006.CrossRefGoogle Scholar
Heumann, R, Korsching, S, Bandtlow, C, Thoenen, H. Changes of nerve growth factor synthesis in nonneuronal cells in response to sciatic nerve transection. J Cell Biol 104(6):1623–1631, 1987.CrossRefGoogle ScholarPubMed
Halvorson, KG, Kubota, K, Sevcik, MA, et al. A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. Cancer Res 65(20):9426–9435, 2005.CrossRefGoogle ScholarPubMed
Sevcik, MA, Ghilardi, JR, Peters, CM, et al. Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization. Pain 115(1–2):128–141, 2005.CrossRefGoogle ScholarPubMed
Peters, CM, Ghilardi, JR, Keyser, CP, et al. Tumor-induced injury of primary afferent sensory nerve fibers in bone cancer pain. Exp Neurol 193(1):85–100, 2005.CrossRefGoogle ScholarPubMed
Hu, P, McLachlan, EM. Macrophage and lymphocyte invasion of dorsal root ganglia after peripheral nerve lesions in the rat. Neuroscience 112(1):23–38, 2002.CrossRefGoogle ScholarPubMed
Woodham, P, Anderson, PN, Nadim, W, Turmaine, M. Satellite cells surrounding axotomised rat dorsal root ganglion cells increase expression of a GFAP-like protein. Neurosci Lett 98(1):8–12, 1989.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×